Top Page
GRAIL Inc
(NASDAQ:GRAL)
GRAIL Inc (GRAL) vs. SPDR S&P 500 ETF (SPY)
GRAIL Inc Business Overview & Revenue Model
GRAIL Inc Earnings Call Summary
GRAIL Inc Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 134.28M | 125.59M | 93.11M | 55.55M | 0.00 | 0.00 |
| Gross Profit | -7.29M | -78.02M | -95.61M | -116.45M | 0.00 | -10.31M |
| EBITDA | -469.82M | -610.17M | -1.35B | -587.70M | -308.73M | -243.14M |
| Net Income | -442.95M | -2.03B | -1.47B | -5.40B | -312.16M | -244.85M |
Balance Sheet | ||||||
| Total Assets | 2.70B | 2.98B | 3.91B | 5.60B | 706.30M | 635.52M |
| Cash, Cash Equivalents and Short-Term Investments | 602.75M | 763.47M | 97.29M | 241.60M | 583.48M | 544.34M |
| Total Debt | 62.16M | 68.14M | 84.41M | 96.01M | 62.99M | 42.04M |
| Total Liabilities | 387.91M | 479.90M | 267.63M | 955.94M | 144.46M | 84.99M |
| Stockholders Equity | 2.31B | 2.50B | 3.65B | 4.65B | 561.84M | 550.53M |
Cash Flow | ||||||
| Free Cash Flow | -371.75M | -582.36M | -608.69M | -584.17M | -243.91M | -249.13M |
| Operating Cash Flow | -370.05M | -577.16M | -595.80M | -561.31M | -232.00M | -245.79M |
| Investing Cash Flow | -462.10M | -551.01M | -12.89M | -22.86M | -12.79M | 133.04M |
| Financing Cash Flow | 0.00 | 1.24B | 463.77M | 604.82M | 275.11M | 160.33M |
GRAIL Inc Technical Analysis
GRAIL Inc Risk Analysis
GRAIL Inc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $18.71B | 27.13 | 31.20% | ― | -2.39% | ― | |
69 Neutral | $27.44B | ― | -29.02% | ― | 38.17% | -28.77% | |
64 Neutral | $3.05B | ― | -17.68% | ― | 22.37% | 86.08% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $11.98B | ― | ― | ― | 30.38% | 24.17% | |
53 Neutral | $1.35B | ― | -12.99% | ― | 10.10% | -44.29% | |
51 Neutral | $613.35M | ― | -72.52% | ― | 0.21% | -233.51% |
GRAIL Inc Corporate Events
On October 18, 2025, GRAIL, Inc. entered into a Securities Purchase Agreement for a private placement, expected to raise approximately $325 million. The proceeds will support GRAIL’s commercial activities, reimbursement efforts, and general corporate purposes, with the closing expected on October 21, 2025. This financing round includes participation from new and existing institutional investors and is anticipated to fund operations into 2030, excluding a separate $110 million investment from Samsung. The private placement is exempt from registration under the Securities Act, with GRAIL agreeing to file a registration statement for the resale of shares.
The most recent analyst rating on (GRAL) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on GRAIL Inc stock, see the GRAL Stock Forecast page.
On October 16, 2025, GRAIL, Inc. entered into a stock purchase agreement with Samsung C&T Corporation and Samsung Electronics to issue and sell shares worth $110 million in a private placement. This strategic collaboration aims to commercialize GRAIL’s Galleri multi-cancer early detection test in South Korea, with potential expansion to Japan and Singapore. The agreement includes conditions such as regulatory approvals and the execution of business and strategic collaboration agreements by early 2026. This partnership is expected to strengthen GRAIL’s market position in Asia and provide financial support for its commercialization and reimbursement efforts.
The most recent analyst rating on (GRAL) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on GRAIL Inc stock, see the GRAL Stock Forecast page.
GRAIL, Inc. has entered into a commercial lease agreement for a new corporate headquarters in Sunnyvale, California, covering approximately 75,556 square feet. The lease, starting in October 2026 and ending in September 2037, includes an initial monthly rent of $449,558 with annual increases, and provides options for expansion and renewal.
The most recent analyst rating on (GRAL) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on GRAIL Inc stock, see the GRAL Stock Forecast page.
Grail Inc faces a potential business risk due to the uncertain regulatory environment surrounding Laboratory Developed Tests (LDTs) and the FDA’s authority to regulate them as medical devices. The company has heavily invested in obtaining a Pre-Market Approval (PMA) for its Galleri test, which could enhance its market position and adoption rates. However, if the FDA cannot enforce its authority, competitors may benefit from less stringent regulations, leading to increased competition. This shift could challenge Grail Inc’s ability to adapt, potentially impacting its business and future prospects.
Grail Inc’s recent earnings call conveyed a predominantly positive sentiment, highlighting significant revenue growth, increased sales, and favorable study outcomes. Despite facing some operational hurdles and reporting a net loss, the overall outlook remains optimistic.
GRAIL, Inc. is a healthcare company focused on early cancer detection using advanced technologies like next-generation sequencing and machine learning, aiming to alleviate the global cancer burden. In its second quarter of 2025, GRAIL reported a total revenue increase of 11% year-over-year, reaching $35.5 million, with its Galleri test revenue growing by 22% to $34.4 million. The company sold over 45,000 Galleri tests in the U.S., marking a 29% increase from the previous year. Despite these gains, GRAIL reported a net loss of $114 million, which includes a $28 million impairment related to Illumina acquisition intangible assets. However, the adjusted EBITDA showed a significant improvement, reducing the loss by 44% compared to the previous year. Key highlights include positive results from the PATHFINDER 2 study, which demonstrated enhanced cancer detection capabilities when Galleri was added to standard care. The company also announced a collaboration with Everlywell to expand access to the Galleri test and its availability at Rush University System for Health. Looking forward, GRAIL remains optimistic about its growth and continued advancements in cancer detection, with plans to present detailed study results at the upcoming European Society for Medical Oncology Congress.
Grail Inc. is conducting a study titled ‘REACH Study: Galleri® in the Medicare Population.’ This multi-center comparative prospective cohort study aims to evaluate the real-world clinical impact, including safety and performance, of the Galleri® test, a blood-based multi-cancer early detection (MCED) test. The study is significant as it seeks to enroll a diverse participant pool, including 20% from under-represented minority groups.